TotalMarketCap

Gilead Sciences

GILDNasdaq United StatesHealth CareBiotechnology: Biological Products (No Diagnostic Substances)

Market cap

$207.794 B

$167.53 -3.98%

Close of 6 Nov 2026

As of 6 Nov 2026, Gilead Sciences (GILD) has a market capitalization of $207.8B. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

$29.4B

#142 by revenue

Earnings

$8.51B

#56 by earnings

Shares outstanding

1,240,338,614

Latest filing cover page

P/E ratio

24.4

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 163 →
  1. #1AmgenAMGN$249.2B
  2. #2Gilead SciencesGILD$207.8B
  3. #3ModernaMRNA$96.5B
  4. #4Argenx SeARGX$55.8B
  5. #5Revolution MedicinesRVMD$38.5B

What if Gilead Sciences were worth as much as…

Open the what-if tool →

Gold $28.2T

$22,765.46

Per share 136× higher

Bitcoin $1.53T

$1,231.80

Per share 7.35× higher

Apple $5.02T

$4,043.88

Per share 24.1× higher

Or at a round number

$500.0B$1.00T$2.00T$5.00T

Where these numbers come from

Share counts and financials for Gilead Sciences are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.